Developed by Lucira Health Inc., both the COVID-19 test and COVID-19 and Flu combination test are highly accurate, authorized by Health Canada, and are now available to consumers, institutions, SMBs, and more.
SUDBURY, Ontario, Feb. 2, 2023 /PRNewswire-PRWeb/ -- RapidScreen Services Inc is a leading provider of technology services and health screening for the film and television industry, as well as government and high-availability businesses. Today, the company announced that it is the exclusive Canadian reseller for the Lucira Check IT COVID-19 Test, the first over-the-counter, Health Canada-authorized COVID-19 molecular test, as well as the Lucira COVID-19 & Flu combination test. These molecular, PCR-quality tests are packaged and designed for self-testing at home, in the office, or on set, making it easy for individuals to take control of their health and protect themselves and their loved ones. RapidScreen's clients include some of the most well-known and respected names in the industry, such as Disney, Netflix, Paramount, Canada Post, and AppleTV.
Developed by Lucira Health Inc., the test has been authorized by Health Canada and is now available to institutions, healthcare providers, agencies, and consumers in time for the busy COVID and Flu season. The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular PCR-quality test that delivers results in 30 minutes or less from one shallow nasal swab.
"We are thrilled to be able to offer these innovative products from Lucira Health to businesses, consumers, and institutions in Canada. The Lucira platform represents a major breakthrough in the fight against infectious diseases and will play a crucial role in keeping communities safe and healthy." said Dr. Dennis Reich, CEO of RapidScreen, "Immediate, reliable and actionable results on common infectious diseases is the game changer everyone is looking for in healthcare."
Lucira Health's single-use test is a compact and convenient solution for quickly and accurately detecting COVID-19, Flu A, and Flu B that fits in the palm of your hand and runs on just two AA batteries. With a simple nasal swab sample, it provides a positive or negative result in 30 minutes or less. Each test comes packaged with everything you need. There is no need to purchase a separate reader or instrument. Simply follow the included instructions to quickly and easily obtain reliable results.
Lucira Health's testing platform is a highly accurate and reliable solution for detecting infectious diseases. The Nucleic Acid Amplification Test (NAAT) used in the platform has sensitivity and specificity comparable to lab-based PCR assays. In November 2020, the Lucira standalone COVID-19 Test was the first at-home molecular COVID-19 test to receive an Emergency Use Authorization (EUA) from the FDA. More recently, the Lucira COVID-19 & Flu Test, which uses the same technology platform, was granted an EUA for point-of-care use. These EUA's speak to the effectiveness and reliability of Lucira's testing platform in detecting COVID-19 and other infectious diseases.
Health Canada has granted authorization under Interim Order No. 3. for the emergency use and commercialization of this first and only at-home test for COVID & Flu. Health Canada's decision is based on performance data including clinical trial results demonstrating comparable sensitivity and specificity to leading lab-based PCR assays.
The test also recently received CE marking, meeting EU health and safety requirements. Submissions to other regulatory authorities are in progress.Inquiries can be sent to RapidScreen – [email protected]
About RapidScreen RapidScreen Services Inc is a leading provider of rapid testing, tracking, and technology services for the film and television industry, small to medium-sized businesses (SMB), and government organisations. Our team of experienced professionals is dedicated to helping our clients keep their communities safe and healthy by providing the most advanced and reliable solutions on the market. From rapid COVID-19 and flu tests to comprehensive tracking and technology services, we have the expertise and resources to meet the needs of a wide range of clients. We are proud to be the exclusive reseller in Canada for the innovative products offered by Lucira Health, and we look forward to helping our clients take advantage of these game-changing solutions. For more information, visit http://www.rapidscreen.com.
About Lucira Health Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialised COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women's health and sexually transmitted infections (STIs). For more information, visit http://www.lucirahealth.ca.
Media Contact
Steve Livshin, RapidScreen, 1 +1 855-487-2743, [email protected]
SOURCE RapidScreen
Advertisement
SUDBURY, Ontario, Feb. 2, 2023 /PRNewswire-PRWeb/ -- RapidScreen Services Inc is a leading provider of technology services and health screening for the film and television industry, as well as government and high-availability businesses. Today, the company announced that it is the exclusive Canadian reseller for the Lucira Check IT COVID-19 Test, the first over-the-counter, Health Canada-authorized COVID-19 molecular test, as well as the Lucira COVID-19 & Flu combination test. These molecular, PCR-quality tests are packaged and designed for self-testing at home, in the office, or on set, making it easy for individuals to take control of their health and protect themselves and their loved ones. RapidScreen's clients include some of the most well-known and respected names in the industry, such as Disney, Netflix, Paramount, Canada Post, and AppleTV.
Advertisement
Developed by Lucira Health Inc., the test has been authorized by Health Canada and is now available to institutions, healthcare providers, agencies, and consumers in time for the busy COVID and Flu season. The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular PCR-quality test that delivers results in 30 minutes or less from one shallow nasal swab.
"We are thrilled to be able to offer these innovative products from Lucira Health to businesses, consumers, and institutions in Canada. The Lucira platform represents a major breakthrough in the fight against infectious diseases and will play a crucial role in keeping communities safe and healthy." said Dr. Dennis Reich, CEO of RapidScreen, "Immediate, reliable and actionable results on common infectious diseases is the game changer everyone is looking for in healthcare."
Lucira Health's single-use test is a compact and convenient solution for quickly and accurately detecting COVID-19, Flu A, and Flu B that fits in the palm of your hand and runs on just two AA batteries. With a simple nasal swab sample, it provides a positive or negative result in 30 minutes or less. Each test comes packaged with everything you need. There is no need to purchase a separate reader or instrument. Simply follow the included instructions to quickly and easily obtain reliable results.
Lucira Health's testing platform is a highly accurate and reliable solution for detecting infectious diseases. The Nucleic Acid Amplification Test (NAAT) used in the platform has sensitivity and specificity comparable to lab-based PCR assays. In November 2020, the Lucira standalone COVID-19 Test was the first at-home molecular COVID-19 test to receive an Emergency Use Authorization (EUA) from the FDA. More recently, the Lucira COVID-19 & Flu Test, which uses the same technology platform, was granted an EUA for point-of-care use. These EUA's speak to the effectiveness and reliability of Lucira's testing platform in detecting COVID-19 and other infectious diseases.
Health Canada has granted authorization under Interim Order No. 3. for the emergency use and commercialization of this first and only at-home test for COVID & Flu. Health Canada's decision is based on performance data including clinical trial results demonstrating comparable sensitivity and specificity to leading lab-based PCR assays.
The test also recently received CE marking, meeting EU health and safety requirements. Submissions to other regulatory authorities are in progress.Inquiries can be sent to RapidScreen – [email protected]
About RapidScreen RapidScreen Services Inc is a leading provider of rapid testing, tracking, and technology services for the film and television industry, small to medium-sized businesses (SMB), and government organisations. Our team of experienced professionals is dedicated to helping our clients keep their communities safe and healthy by providing the most advanced and reliable solutions on the market. From rapid COVID-19 and flu tests to comprehensive tracking and technology services, we have the expertise and resources to meet the needs of a wide range of clients. We are proud to be the exclusive reseller in Canada for the innovative products offered by Lucira Health, and we look forward to helping our clients take advantage of these game-changing solutions. For more information, visit http://www.rapidscreen.com.
About Lucira Health Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialised COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women's health and sexually transmitted infections (STIs). For more information, visit http://www.lucirahealth.ca.
Media Contact
Steve Livshin, RapidScreen, 1 +1 855-487-2743, [email protected]
SOURCE RapidScreen
